Literature DB >> 19473999

Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.

A Mehta1, J T R Clarke, R Giugliani, P Elliott, A Linhart, M Beck, G Sunder-Plassmann.   

Abstract

BACKGROUND: Fabry disease is a rare X-linked lysosomal storage disorder characterised by severe multisystemic involvement that leads to major organ failure and premature death in affected men and women. Over the past 7 years, the Fabry Outcome Survey (FOS) has collected data on the natural history of Fabry disease, and the long-term efficacy and safety of enzyme-replacement therapy. This paper provides an update on the first analysis of FOS data.
DESIGN: Baseline data on clinical manifestations and causes of death in a cohort of 1453 patients (699 male, 754 female) from 19 countries worldwide were analysed. Causes of death of affected relatives were analysed separately.
RESULTS: The most frequently reported signs and symptoms of Fabry disease were neurological. Cardiac, ocular, gastrointestinal, dermatological, auditory and renal manifestations were also common. The principal causes of death among 181 affected relatives of patients in FOS (most of whom had died before 2001) were renal failure in males (42%) and cerebrovascular disease in females (25%). In contrast, of the 42 patients enrolled in FOS whose deaths were reported between 2001 and 2007, cardiac disease was the main cause of death in both male (34%) and female (57%) patients.
CONCLUSION: These data suggest that the importance of renal disease as a cause of death in patients with Fabry disease is decreasing while the importance of cardiac disease is increasing. This pattern probably reflects improvements in the management of renal disease in patients with Fabry disease.

Entities:  

Mesh:

Year:  2009        PMID: 19473999     DOI: 10.1136/jmg.2008.065904

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  88 in total

Review 1.  Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.

Authors:  Carla E M Hollak; Johannes M F G Aerts; Ségolène Aymé; Jeremy Manuel
Journal:  Orphanet J Rare Dis       Date:  2011-04-16       Impact factor: 4.123

Review 2.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

Authors:  Praveen G Ranganath; Albree Tower-Rader
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

Review 3.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

4.  Severe bradyarrhythmia linked to left atrial dysfunction in Fabry disease-A cross-sectional study.

Authors:  Lu Zhao Di; Maxime Pichette; Réginald Nadeau; Daniel G Bichet; Frédéric Poulin
Journal:  Clin Cardiol       Date:  2018-09-20       Impact factor: 2.882

5.  Antiepileptic medications increase osteoporosis risk in male fabry patients: bone mineral density in an Australian cohort.

Authors:  Andrew Talbot; Joanna R Ghali; Kathy Nicholls
Journal:  JIMD Rep       Date:  2014-07-26

6.  Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS).

Authors:  Tomas Palecek; Jitka Honzikova; Helena Poupetova; Hana Vlaskova; Petr Kuchynka; Lubor Golan; Sudheera Magage; Ales Linhart
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

7.  Fabry disease in latin america: data from the fabry registry.

Authors:  J Villalobos; J M Politei; A M Martins; G Cabrera; H Amartino; R Lemay; S Ospina; S Suarez Ordoñez; C Varas
Journal:  JIMD Rep       Date:  2012-07-06

8.  Pituitary function and morphology in Fabry disease.

Authors:  Luigi Maione; Fabio Tortora; Roberta Modica; Valeria Ramundo; Eleonora Riccio; Aurora Daniele; Maria Paola Belfiore; Annamaria Colao; Antonio Pisani; Antongiulio Faggiano
Journal:  Endocrine       Date:  2015-04-21       Impact factor: 3.633

9.  Age at First Cardiac Symptoms in Fabry Disease: Association with a Chinese Hotspot Fabry Mutation (IVS4+919G>A), Classical Fabry Mutations, and Sex in a Taiwanese Population from the Fabry Outcome Survey (FOS).

Authors:  Hao-Chuan Liu; Amandine Perrin; Ting-Rong Hsu; Chia-Feng Yang; Hsiang-Yu Lin; Wen-Chung Yu; Dau-Ming Niu
Journal:  JIMD Rep       Date:  2015-03-12

Review 10.  Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Authors:  Elizabeth A Ottinger; Mark L Kao; Nuria Carrillo-Carrasco; Nicole Yanjanin; Roopa Kanakatti Shankar; Marjo Janssen; Marcus Brewster; Ilona Scott; Xin Xu; Jim Cradock; Pramod Terse; Seameen J Dehdashti; Juan Marugan; Wei Zheng; Lili Portilla; Alan Hubbs; William J Pavan; John Heiss; Charles H Vite; Steven U Walkley; Daniel S Ory; Steven A Silber; Forbes D Porter; Christopher P Austin; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.